Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment.

Wei-Xiang Qi,Shengguang Zhao,Jiayi Chen
DOI: https://doi.org/10.2217/fon-2019-0352
2019-01-01
Future Oncology
Abstract:Aim: To investigate the risk factors for developing osteonecrosis of jaw (ONJ) in advanced cancer patients with bone metastases underwent zoledronic acid (ZA) treatment. Materials & methods: Univariate and multivariate logistic regression analyses were performed to investigate factors associated with developing ONJ in advanced cancer patients. Results: A total of 2214 advanced cancer patients were included. Univariate and multivariate logistic regression analyses for risk factors associated with ONJ were older age (>= 66 years, hazards ratio [HR]: 3.21; p = 0.007), anemia (HR: 3.29; p = 0.006) and duration of ZA exposure (between 1 and 2 years, HR: 3.91, p = 0.01; >= 2 years, HR: 8.07, p < 0.001), respectively. Conclusion: Patients with older age, anemia and/or more than 1 year of ZA treatment are at high risk of developing ONJ.
What problem does this paper attempt to address?